OBJECTIVES: Pharmacoeconomics is a newly developed discipline in China. Economic assessment is increasingly used as supportive evidence driving pricing and reimbursement decisions. Nevertheless, guidelines are necessary to homogenise their practice and promote their use. Among the different guidelines that have been published, two published in 2006 and in 2011 significantly support the implementation of pharmacoeconomics in China. Since multinational pharmaceutical companies are increasingly present in the Chinese market, this tends to increase the spread of such publications. This paper aims to quantify the impact of the introduction of guidelines as incentives to publish international articles in China.  METHODS: A literature review was undertaken using the Pubmed database. Keywords used in the search strategy were: ‘China’, ‘Pharmacoeconomics’, ‘Economic Evaluation’, ‘Cost-Effectiveness’, ‘Cost of Illness’, ‘Cost-Benefit’, ‘Cost-Utility’, ‘Cost-Minimization’ and ‘Budget Impact’. We used a timeframe of ten years before the first pharmacoeconomic guideline to present. This corresponds to 01/01/1996 to 14/03/2014. In order to take into consideration only international publications, only English papers were selected. A final screening was performed to select the articles directly related to pharmacoeconomics and only in China.  RESULTS: